XAIR
Beyond Air, Inc.
$0.4101
+2.01%
$5.1M
No data for this timeframe.
Vol
Market Cap$5.1M
Cap SizeNano Cap
Analyst ConsensusStrong Buy (82%)
Inst. Holders3 funds
Inst. Value$44.0K
Inst. Activity1 buys / 2 sells
Reddit Sentiment29° Bearish
SEC Reports2
Press Releases2
Exchange Nasdaq·Sector Surgical & Medical Instruments & Apparatus·Inc. DE·CIK 0001641631·Prev Close $0.4020
Recent Activity
Apr 15, 2026
SEC
Beyond Air, Inc. received a Nasdaq delisting notice due to non-compliance with the $1.00 minimum bid price requirement a
8-K — Impact 7/10
Apr 10, 2026
SEC
Beyond Air, Inc. (XAIR) received a delisting notice from Nasdaq for failing to maintain a $1.00 minimum bid price for 30
8-K — Impact 8/10
Inst.
VANGUARD GROUP INC — TRIM
60,437 shares ($43.9K)
Inst.
BANK OF AMERICA CORP — TRIM
68 shares ($49.00)
Apr 20, 2026
Press
Beyond Air's subsidiary Beyond Cancer presented updated Phase 1 trial data at AACR showing prolonged survival in heavily
Impact 7/10
Apr 20, 2026
fda
Beyond Cancer Reports Updated Survival and Safety Data from Phase 1 UNO Trial Presented at AACR 2026
<p align="center"><em>Updated AACR poster data show continued survival follow-up in heavily pre</em>
Mar 17, 2026
Press
Beyond Cancer, Ltd., a subsidiary of Beyond Air (XAIR), announced early clinical activity and a favorable safety profile
Impact 7/10
Price Targets
$8.67
+2013.3% upside
Strong Buy
Current $0.4101
Low $2.00
Median $10.00
High $14.00
3 analysts
$2.00
$14.00
Analyst Ratings
2Strong Buy
7Buy
2Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Mar 27, 2026 | D. Boral Capital | MAINTAIN | Buy → Buy |
| Mar 18, 2026 | D. Boral Capital | MAINTAIN | Buy → Buy |
| Mar 10, 2026 | D. Boral Capital | MAINTAIN | Buy → Buy |
| Jan 21, 2026 | D. Boral Capital | MAINTAIN | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.45 | $-0.45 — $-0.45 | 1 | |
| Next Q | $-0.48 | $-0.55 — $-0.42 | 68% YoY | 2 |
| Current FY | $-4.05 | $-4.05 — $-4.05 | 1 | |
| Next FY | $-1.66 | $-1.66 — $-1.66 | 59% YoY | 1 |
Latest Reports
BULLISH
Press
7/10
Beyond Air's subsidiary Beyond Cancer presented updated Phase 1 trial data at AACR showing prolonged survival in heavily
Apr 20, 2026
BEARISH
8-K
7/10
Beyond Air, Inc. received a Nasdaq delisting notice due to non-compliance with the $1.00 minimum bid price requirement a
Apr 15, 2026
BEARISH
8-K
8/10
Beyond Air, Inc. (XAIR) received a delisting notice from Nasdaq for failing to maintain a $1.00 minimum bid price for 30
Apr 10, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| VANGUARD GROUP INC | $43.9K | TRIM |
| BANK OF AMERICA CORP | $49.00 | TRIM |
| MORGAN STANLEY | $36.00 | ADD |
Reddit Sentiment
29°
Bearish
Bearish
Neutral
Bullish
3 institutional holders with $44.0K total value (60,555 shares) as of 2025-Q4. Top holders: VANGUARD, BANK, MORGAN. Net selling activity: 2 institutions trimmed/exited vs 1 added.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | VANGUARD GROUP INC | 60,437 | $43.9K | 99.8% | TRIM -42.1% |
| 2 | BANK OF AMERICA CORP /DE/ | 68 | $49.00 | 0.1% | TRIM -37.6% |
| 3 | MORGAN STANLEY | 50 | $36.00 | 0.1% | ADD +25.0% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| VANGUARD GROUP INC | TRIM | 104,409 | 60,437 | -42.1% | $43.9K | 2025-Q4 |
| BANK OF AMERICA CORP /DE/ | TRIM | 109 | 68 | -37.6% | $49.00 | 2025-Q4 |
| MORGAN STANLEY | ADD | 40 | 50 | +25.0% | $36.00 | 2025-Q4 |
| VANGUARD GROUP INC | NEW | — | 104,409 | — | $241.2K | 2025-Q3 |
| RENAISSANCE TECHNOLOGIES LLC | EXIT | 358,200 | 0 | -100.0% | $0.00 | 2025-Q3 |
| UBS Group AG | EXIT | 152,062 | 0 | -100.0% | $0.00 | 2025-Q3 |
| VANGUARD GROUP INC | EXIT | 1,451,898 | 0 | -100.0% | $0.00 | 2025-Q3 |
| RENAISSANCE TECHNOLOGIES LLC | ADD | 196,200 | 358,200 | +82.6% | $61.7K | 2025-Q2 |
| UBS Group AG | DOUBLED | 39,653 | 152,062 | +283.5% | $26.2K | 2025-Q2 |
| RENAISSANCE TECHNOLOGIES LLC | DOUBLED | 64,900 | 196,200 | +202.3% | $53.5K | 2025-Q1 |
| CITADEL ADVISORS LLC | DOUBLED | 23,100 | 46,300 | +100.4% | $12.6K | 2025-Q1 |
| RENAISSANCE TECHNOLOGIES LLC | DOUBLED | 20,100 | 64,900 | +222.9% | $23.3K | 2024-Q4 |
| UBS Group AG | DOUBLED | 183 | 35,206 | +19138.3% | $12.6K | 2024-Q4 |
| CITADEL ADVISORS LLC | NEAR_EXIT | 124,121 | 23,100 | -81.4% | $8.3K | 2024-Q4 |
| MORGAN STANLEY | NEAR_EXIT | 41,626 | 5,818 | -86.0% | $2.1K | 2024-Q4 |
| MORGAN STANLEY | TRIM | 148,911 | 41,626 | -72.0% | $16.1K | 2024-Q3 |
No insider trading data available yet. Insider transactions are collected from SEC Form 4 filings.
2 SEC filing reports analyzed. Sentiment: 0 bullish, 2 bearish, 0 mixed, 0 neutral. Avg impact: 7.5/10.
Current analyst consensus: Strong Buy (82% buy). Based on 11 analysts: 2 strong buy, 7 buy, 2 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$8.67 mean target
+2013.3% upside
Strong Buy (3.00)
$2.00 Low
$14.00 High
| Metric | Value |
|---|---|
| Current Price | $0.4101 |
| Target Low | $2.00 |
| Target Mean | $8.67 |
| Target Median | $10.00 |
| Target High | $14.00 |
| # Analysts | 3 |
| Recommendation | Strong Buy (3.00) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-03-31 |
$-0.45 | $-0.45 | $-0.45 | — | +0.0% | 0↑ 1↓ | $0.0B | 98.3% | 1 |
| Next Q 2026-06-30 |
$-0.48 | $-0.55 | $-0.42 | 68.3% | +0.0% | 1↑ 1↓ | $0.0B | 23.2% | 2 |
| Current FY 2026-03-31 |
$-4.05 | $-4.05 | $-4.05 | — | +0.0% | 0↑ 1↓ | $0.0B | 117.7% | 1 |
| Next FY 2027-03-31 |
$-1.66 | $-1.66 | $-1.66 | 59.0% | +0.0% | 0↑ 1↓ | $0.0B | 58.1% | 1 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.450 | |
| 7d ago | $-0.450 | |
| 30d ago | $-0.450 | |
| 60d ago | $-0.540 | +0.090 |
| 90d ago | $-0.270 | -0.180 |
1 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 0 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Mar 27, 2026 | D. Boral Capital | MAINTAIN | Buy | Buy |
| Mar 18, 2026 | D. Boral Capital | MAINTAIN | Buy | Buy |
| Mar 10, 2026 | D. Boral Capital | MAINTAIN | Buy | Buy |
| Jan 21, 2026 | D. Boral Capital | MAINTAIN | Buy | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| May 1, 2026 | 2 | 7 | 2 | 0 | 0 | 82% | |
| Apr 1, 2026 | 2 | 7 | 2 | 0 | 0 | 82% | |
| Mar 1, 2026 | 2 | 7 | 2 | 0 | 0 | 82% | |
| Feb 1, 2026 | 2 | 7 | 2 | 0 | 0 | 82% | |
| Jan 1, 2026 | 2 | 7 | 2 | 0 | 0 | 82% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
29°
Bearish
Bearish
Neutral
Bullish
3 mentions
0 bullish
3 bearish
3 time periods
Reddit Sentiment History
| Date | Mentions | Sentiment | Bullish | Bearish | Threads |
|---|---|---|---|---|---|
| Apr 15, 2026 | 1 | 40° Cool | 0 | 1 | 1 |
| Apr 15, 2026 | 1 | 40° Cool | 0 | 1 | 1 |
| Feb 22, 2026 | 1 | 40° Cool | 0 | 1 | 1 |
Recent Reddit Threads
XAIR stock. Is it doomed?
▲ 1
💬 1
⚡ 0.5
XAIR and RR ( cut losses or hold )
▲ 1
💬 0
⚡ 0.0
Apr 20, 2026
fda
Beyond Cancer Reports Updated Survival and Safety Data from Phase 1 UNO Trial Presented at AACR 2026
<p align="center"><em>Updated AACR poster data show continued survival follow-up in heavily pre</em><em>‑</em><em>treated patients following a single
Apr 15, 2026
other
Beyond Air to Participate in the D. Boral Capital Global Conference 2026
<p>GARDEN CITY, N.Y., April 15, 2026 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR), a commercial-stage medical device and biopharmaceutical co
Mar 17, 2026
fda
Beyond Cancer Reports Early Clinical Activity and Favorable Safety Profile with Interim Data from Phase 1 UNO Trial
Data was published in the Online Itinerary Planner for the 2026 AACR Annual Meeting, and is scheduled to be presented at the meeting on April 19th <pr
Mar 11, 2026
other
Beyond Air to Participate in the 38th Annual Roth Conference in March
<p align="justify">GARDEN CITY, N.Y., March 11, 2026 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) ("Beyond Air" or the "Company"), a commerci
Mar 10, 2026
other
Beyond Air® Announces Termination of Agreement to Sell Its NeuroNOS Subsidiary to XTL Biopharmaceuticals Ltd.
<p align="justify">GARDEN CITY, N.Y., March 10, 2026 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commerci